Form 4: AVITA Medical Director Jeremy Curnock Cook Reports Significant Equity Awards Following Stockholder Approval

AVITA Medical, Inc. Director Jeremy Curnock Cook reported the acquisition of 10,022 restricted stock units and 4,295 stock options, granted on January 21, 2025, following stockholder approval on June 4, 2025.

Summary

• Director Jeremy Curnock Cook of AVITA Medical, Inc. (RCEL) acquired 10,022 Restricted Stock Units (RSUs) and 4,295 stock options.
• The RSUs represent a contingent right to one share of Common Stock each and are subject to time-based vesting, scheduled to vest 12 months after the grant date of January 21, 2025.
• The stock options allow the purchase of 4,295 shares of Common Stock at an exercise price of $8.73 per share, which was the closing price on Nasdaq on the grant date.
• These options become exercisable on January 21, 2026, and have an expiration date of January 21, 2035.
• Both the RSU and option grants were subject to and received approval from the Company's stockholders on June 4, 2025.
• Following these transactions, Mr. Cook beneficially owns a total of 39,836 shares of Common Stock, which includes the newly acquired unvested RSUs.

Sentiment

Score: 7

Explanation: The filing indicates a director receiving equity compensation, which is a positive sign of alignment with shareholder interests and standard corporate practice. It does not contain any negative operational or financial news.

Positives

• Director Jeremy Curnock Cook received significant equity awards (10,022 RSUs and 4,295 stock options), which aligns his interests with long-term shareholder value.
• The grants were approved by stockholders, indicating support for the compensation structure for non-executive directors and adherence to corporate governance practices.

Risks

• The ultimate value of the Restricted Stock Units and stock options is contingent upon the future performance and market price of AVITA Medical's common stock.
• The RSUs are unvested and the options are unexercised, meaning they do not provide immediate liquidity or full ownership rights until their respective vesting and exercisability conditions are met.

Future Outlook

This Form 4 primarily reports past equity compensation transactions and does not contain forward-looking statements regarding the company's financial performance or strategic outlook. It indicates future vesting and exercisability dates for the granted equity awards.

Industry Context

This filing is a standard insider transaction disclosure, reflecting a common practice of compensating non-executive directors with equity awards. This approach is widely adopted across various industries, including biotechnology and medical devices, to align the interests of directors with those of long-term shareholders. It does not provide specific industry-wide trends or competitive analysis beyond this standard practice.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) and stock options to non-executive directors is a common practice in the biotechnology and medical device industry, similar to compensation structures observed at companies like Integra LifeSciences Holdings Corporation or CONMED Corporation.
• The 12-month vesting schedule for RSUs is typical for time-based equity awards, designed to ensure continued commitment and retention of directors.
• The exercise price of options being set at the closing price on the grant date ($8.73) is standard for 'at-the-money' options, providing upside potential tied directly to stock appreciation.

Corporate Governance

Related Party Transactions

• The equity awards granted to Director Jeremy Curnock Cook constitute a related party transaction, which is a standard form of compensation for directors and has been disclosed in this filing.

Stakeholder Impact

• Shareholders: The equity awards align the director's long-term interests with those of the shareholders, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The Restricted Stock Units (RSUs) are scheduled to vest on January 21, 2026.
• The stock options will become exercisable on January 21, 2026, and will expire on January 21, 2035.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards, Beneficial Ownership, Corporate Governance